Botulinum toxin type B in blepharospasm and hemifacial spasm

Botulinum neurotoxins (BTXs) inhibit the presynaptic release of acetylcholine causing a cholinergic denervation that results in sustained muscle weakness and have been used in the past 20 years to induce selective blocking of hyperactive striatal (and smooth) muscles. All the different seven serotypes of BTXs have improved and are being investigated. Two controlled clinical trials have demonstrated that local intramuscular injections of BTX-B are effective in the treatment of cervical dystonia in patients with BTX-A resistant disease, as well as in patients with BTX-A resistant disease (secondary non-responders). BTX-B was found to be effective in both studies, with a significant improvement observed in all the parameters investigated (severity, disability, and pain); action was found to last as long as 16 weeks. Based on these favourable results, we investigated BTX-B treatment in blepharospasm (BLS), another common form of focal dystonia, and in hemifacial spasm (HFS). Indeed, despite BTX-A being an efficacious treatment for these conditions, a percentage of patients still shows a suboptimal response, requiring long term treatments. They could, therefore, benefit from the availability of another botulinum toxin serotype.

Blepharospasm

We studied 13 subjects (10 women and 3 men; mean (SD) age at onset 51.5 (15.0) years; mean disease duration 9.1 (8.1) years) with BLS. BLS was diagnosed as idiopathic focal dystonia in 12 patients, and tardive dystonia in one case. All patients had received BTX-A before, with a moderate to good response. Patients were excluded if they had received a BTX-A injection in the past three months for their BLS. After an informed consent was obtained, four pretarsal injections were placed around each eye; the fixed total dose for each treatment was 2500 units (0.8 ml of a solution obtained by adding 0.3 ml of saline to 0.5 ml of the commercially available BTX-B solution). Before each treatment, patients were assessed with an objective rating scale for dystonia (Burke-Fahn-Marsden scale, severity factors, items for BLS and mouth averaged; this scale was used in the absence of validated rating scales for HFS); efficacy was assessed at the time of the peak effect with the same objective rating scale and the subjective visual analogue scale reported above. Each patient received a single treatment. Latency and duration of the effect were assessed as above.

Results of the trial are reported in table 1. Only two patients rated the efficacy of BTX-B as superior to BTX-A and preferred to continue treatment with BTX-B. The drug was generally well tolerated, with the most common adverse effect being local pain during the injection, which was reported by 7 of 11 patients. Other common side effects of BTX-A treatment were negligible.

<table>
<thead>
<tr>
<th>Table 1 Response to BTX-B injections</th>
</tr>
</thead>
<tbody>
<tr>
<td>BLS</td>
</tr>
<tr>
<td>Latency of response (days)</td>
</tr>
<tr>
<td>Duration of response (days)</td>
</tr>
<tr>
<td>Objective rating scale (points)</td>
</tr>
<tr>
<td>Subjective visual analogue scale (%)</td>
</tr>
</tbody>
</table>

Results are expressed as mean (SD). *Student’s t test between before and after injection: p<0.001.

Comment

This open pilot trial, which is the first to use BTX-B in a neurological condition other than cervical dystonia, suggests that BTX-B is an effective and safe treatment for both BLS and HFS. The time course and magnitude of the improvement observed in our study are similar to those reported in trials with BTX-A for the same conditions, while the duration of the effect appears shorter as the mean duration of effect with BTX-A in these neurological conditions is 12–16 weeks. The only peculiar side effect was local pain during the injection, which has not been reported before in trials with BTX-B. This event might be related to the fact that BTX-B is available in a liquid preparation, which has different biochemical properties than the reconstituted solution of BTX-A. The severe, adverse reaction reported in a single patient with BLS has not been described in previous trials using this compound for cervical dystonia and has rarely been reported in conjunction with BTX-A use; it should, however, not discourage the planning of further dose ranging studies of BTX-B and studies on larger series of patients designed to compare the effect of BTX-B with both placebo and BTX-A in different neurological disorders.

Botulinum neurotoxins (BTXs) inhibit the presynaptic release of acetylcholine causing a cholinergic denervation that results in sustained muscle weakness and have been used in the past 20 years to induce selective blocking of hyperactive striatal (and smooth) muscles. All the different seven serotypes of BTXs have improved and are being investigated. Two controlled clinical trials have demonstrated that local intramuscular injections of BTX-B are effective in the treatment of cervical dystonia in patients with BTX-A resistant disease, as well as in patients with BTX-A resistant disease (secondary non-responders). BTX-B was found to be effective in both studies, with a significant improvement observed in all the parameters investigated (severity, disability, and pain); action was found to last as long as 16 weeks. Based on these favourable results, we investigated BTX-B treatment in blepharospasm (BLS), another common form of focal dystonia, and in hemifacial spasm (HFS). Indeed, despite BTX-A being an efficacious treatment for these conditions, a percentage of patients still shows a suboptimal response, requiring long term treatments. They could, therefore, benefit from the availability of another botulinum toxin serotype.
patients. Sodium channels. regard, it resembles the dysgeusia known symptom of the disease in our patients. In this To our knowledge, dysgeusia has not been riluzole and articles/elescorial1998.htm). Treatment with Escorial criteria (http://www.wfnals.org/ wave latencies. Thus motor neuropathy with physiological testing showed active denervation. Peripheral electro- patients. Motor evoked potentials revealed for paraneoplastic autoantibodies (Hu, Yo, Ri, cerebrospinal fluid studies were normal. Tests the test did not reveal hypogeusia for any qual- quinine (0.00016 mM) was undertaken. Al- symptoms or at the time of admission. Oral non-prescription drugs during the months examination was normal. The patients had not taken prescription or neuropeptide drugs during the months preceding the symptoms, or at the initiation of symptoms or at the time of admission. Oral hygiene was good in both cases and serosto- Family history was negative. The occupational and chemical exposure history was unremarkable. Spatial gustatory function testing with sodium chloride (0.04 and 0.32 M), sucrose (0.07 and 0.32 M), citric acid (0.01 and 0.02 M), and quinine (0.00016 mM) was undertaken. Although both patients described the perception of a bitter taste throughout the examination, the test did not reveal hypogeusia for any quality. In both cases routine blood chemistry and cerebrospinal fluid studies were normal. Tests for paraneoplastic autoantibodies (Hu, Yo, Ri, Ma, Ta, CV2) were negative. Cranial and spinal magnetic resonance imaging showed mild bilateral cerebellar atrophy. The precentral gyrus of both patients. Motor evoked potentials revealed slowed conduction. Peripheral electrophysiologic testing showed active denervation, normal nerve conduction, and normal F wave latencies. Thus motor neuropathy with multifocal conduction block, cervical myelopathy, and paraneoplastic motor neurone disease could be excluded. A diagnosis of clinically definite ALS was made, based on the revised El Escolar criteria (http://www.sfwnals.org/articles/escolar1998.htm). Treatment with riluzole and atocopherol was initiated in both patients.

Comment

To our knowledge, dysgeusia has not been described in this disease. The persistent perception of a bitter taste developed as a early symptom of the disease in our patients. In this regard, it resembles the dysgeusia known from ciguatera food poisoning, which is thought to provide a bitter taste by blocking sodium channels. However, other sensory symptoms were absent, both clinically and electrophysiologically. The chorda tympani branch of the facial nerve carries taste sensations from the anterior two thirds of the tongue, whereas the glossopharyngeal nerve and the vagus nerve innervate the posterior third and the epiglottis. It has been shown experimentally and clinically that anaesthesia of the chorda tympani nerve branch results in intensified perception of bitter taste from the posterior tongue, suggesting that the same way of the chorda tympani normally inhibits the glossopharyngeal and vagus nerve input. In fact, spontaneous bitter taste dysgeusia (phantogeusia) similar to that perceived by our patients was observed in the posterior tongue after anaesthesia of the chorda tympani.7 Hence it may be speculated that mild sensory anaesthesia of the chorda tympani branches may be responsible for our findings. Sensory findings have indeed been described in ALS. However, if at all, they develop relatively late in the disease.4 Furthermore, the spatial gustatory function test did not confirm our hypothesis. Alternatively, the dysgeusia may be of central nervous origin. Both patients presented with bilateral oral facial paresis reflecting a prominent bulbar involvement in the dis- the test may be interpreted as supportive of our hypothesis; however, further clarification is needed. Thus it is still debatable whether degeneration of the brain stem sensory tract nucleus may be responsible for the dysgeusia in our patients. Interestingly, dysfunction of the autonomous nervous system—which in part is also regulated by the solitary tract nucleus—has been described in ALS,5 supporting the view that this disease may be a multisystem disorder. Thus dysgeusia may indicate brain stem involvement in the disease. As a bulbar onset of ALS is an important predictor of the disease course, our finding may also be of prognostic value. We cannot provide a definite neuroanatomical basis for our observation, but we believe that future studies may be able to address these issues.

G C Petzold, K M Einhäupl, J M Valdueza Department of Neurology, Charité Hospital, Humboldt University, Schumannstr 20/21, 10098 Berlin, Germany Competing interests: none declared Correspondence to: Dr Petzold; gaborn.petzold@charite.de

References

1 Pearn J. Neurology of ciguatera. J Neurol Neurosurg Psychiatry 2001;70:4–8

Schizophrenia and episodic ataxia type 2

The frequent co-occurrence of degenerative cerebellar pathology and schizophrenia, as well as the recently reported increased association rate between autosomal dominant ataxias and major psychosis, strongly suggests the involvement of the cerebellum in the pathophysiology of schizophrenia.6 The analysis of associations between psychosis and neurodegenerative diseases may improve our understanding of the pathomechanisms of schizophrenia and facilitate the search for susceptibility genes for this disorder.7 To our best knowledge, there have been no previous reports about an association of schizophrenia and the periodic ataxic dominant ataxias, such as episodic ataxia type 1 and type 2 (EA1 and EA2). We present a case of a young man who has been diagnosed with paraneoplastic and schizophrenia (ICD-10: F20.0) and episodic ataxia type 2.

Case study

The patient, a man aged 27 years, was first admitted to our hospital with psychotic symptoms in June 1995. He presented with paranoid delusions and delusions of reference, acoustic hallucinations (commenting voices), formal thought disorder, and behaviour disorganisation, as well as negative symptoms such as blunted affect, poor rapport, and lack of spontaneity. He was diagnosed as having paranoid schizophrenia (ICD-10: F20.0) and showed a PANSS (positive and negative symptom scale) total score of 688.

The patient was initially treated with risperidone (6 mg/d) which led to a slight improvement in his psychotic symptoms. After discharge from our hospital in September 1995 he regularly attended our outpatient clinic. Despite treatment with risperidone and later with haloperidol decanoate (20 mg/2 weeks), he continued to have chronic psychotic symptoms, with particular attention to his admission in April 2001. At this admission he was suffering from severe psychosis (paranoid delusions, acoustic hallucinations, formal thought disorder, and behavioural disorganisation) and negative symptoms (fig 1). Antipsy- chotic treatment withquetiapine (800 mg/d; 4 weeks) and subsequently with amisulpride (600 mg/d; 4 weeks) did not lead to any improvement in the psychosis. At this time, a neurological investigation showed gage evoked nystagmus and upward gaze palsy, though attacks of ataxia had neither been reported by the patient nor noticed by the nurses.

Because of persistence of the psychotic symptoms, we began treatment with clozap- ine (300 mg/d) and noticed a slight deterioration in psychosis over the next four weeks despite sufficient serum levels of cloza- pine. At that time the first severe ataxia attacks appeared. They were manifested by gait ataxia, dysarthria, and slight intention tremor of the upper extremities and persisted for at least several hours. After other causes of cerebellar dysfunction—such as inflammatory, toxic, and vascular disorders—had been excluded, the patient was diagnosed as having episodic ataxia type 2 because he met the following clinical diagnostic criteria: duration of episodes (hours to days), gait and stance ataxia, interictal absence of most symptoms (except oculomotor deficits). Consequently, we began treatment with acetazolamide (200 mg twice daily) and switched the antipsy- chotic medication from clozapine to potent thioridazine (400 mg/d). This led to both a complete elimi- nation of ataxia episodes and a gradual amelio- ration of the psychotic symptoms. At the time of discharge six weeks later, the patient’s PANSS total score was 90. At all subsequent follow up investigations undertaken monthly until December 2002 the psychotic symp- toms remained unchanged (fig 1) and there was no recurrence of the ataxia attacks.
Episodic ataxia in this patient obviously follows an autosomal dominant trait. The patient’s mother suffers from cerebellar atrophy with severe gait and limb ataxia, dysarthria, and oculomotor deficits. Her father is reported to have had oculomotor deficits as well.

At the age of 12 months, a neurological examination of our patient showed saccadic pursuit and vertical spontaneous nystagmus. Since the age of 18 months, spells of gait and stance ataxia have been described (15 to 20 minutes long, one to four times in four to six weeks). At the age of three years and nine months, a neurological investigation showed gaze evoked nystagmus, saccadic pursuit, and absence of optokinetic nystagmus (both horizontal and vertical). At that age a suspicion of migraine was raised but not confirmed. At the same time abnormal EEG patterns with sharp waves over the left temporal lobe were reported.

Recent EEGs done before, during, and after treatment with clonazepam showed abnormal bilateral theta-delta activity (4–7 cps and 2–3 cps) in the temporal and parietal regions. Magnetic resonance (MR) imaging done in 1995, 1997, and 2001 showed no signs of atrophy or cerebral signal alteration. Proton MR spectroscopy done in July 2001 revealed decreased N-acetylaspartate to creatine ratios in the cerebellar vermis region and left cerebellar hemisphere. On 18F-iodomazenil SPECT in July 2002, there was a reduced density of the GABA(A)-benzodiazepine receptor complex in the cerebellum as well as in the frontal dorsolateral and occipital regions.

**Comment**

This case shows an association between clinically diagnosed episodic ataxia type 2 and schizophrenia. Cessation of ataxia episodes as a response to treatment with acetazolamide supports the clinical diagnosis of EA2 and rules out alternative pathologies such as SCA6, a disorder of chromosome 19, which is not associated with major psychosis. SCA6, a disorder of chromosome 19, is associated with schizophrenia, but patients with SCA8 have shown an increased rate of association with major psychosis. Until now there have been no reports of an association between episodic ataxia and schizophrenia.

Autosomal dominant episodic ataxia type 2 is assumed to be caused by mutation in the gene CACNA1A (chromosome 19p13.1), which encodes the Ca2.1 subunit of the voltage-gated P/Q calcium channels. As calcium channels are involved in the modulation of neurotransmitter release, it has been hypothesized that they play a role in the pathophysiology of schizophrenia.

Cerebellar atrophy as well as mild cerebellar dysfunction are already known to be associated with schizophrenia. This is the first case of a patient suffering from episodic cerebellar ataxia and schizophrenia, and it points to a possible role of ion channel polymorphism in the pathophysiological mechanisms of schizophrenia.

**Association of cardiomyopathy caused by autonomic nervous system impairment with the Miller Fisher syndrome**

We report a case of Miller Fisher syndrome associated with reversible left ventricular wall motion abnormalities similar to takotsubo-shaped cardiomyopathy.

**Case report**

A 58-year-old man was admitted to our hospital because of ataxia, ophthalmoplegia, and dysarthria. He had a 10-year history of hypertension. Four weeks before admission, he had common-cold-like symptoms. Ten days before admission, he developed difficulties with walking and speaking. The next day he was unable to walk or lift his eyelids. He was admitted to another hospital, where he was diagnosed as having a brain stem infarct. During admission, he developed tightness in the chest for three to four days, which improved spontaneously. Because of exacerbation of his neurological symptoms, he was transferred to our hospital.

On initial physical examination, his blood pressure was 158/106 mm Hg, and his heart rate was 108 beats/min and in regular rhythm. He was afebrile and had no respiratory difficulty. On neurological examination, he was fully orientated. His pupils were slightly mydriatic bilaterally (right 6 mm, left 6.5 mm) and the light reflex was absent on both sides. Complete ophthalmoplegia and peripheral facial palsy were observed bilaterally. He had severe dysarthria with restricted movements of the soft palate and tongue. Although muscle strength was preserved, deep tendon reflexes were absent in the four extremities. The plantar responses were flexor. There was no definite involvement of sensory functions. Ataxia was observed in the four extremities.

Routine laboratory tests were normal except for a slightly increased white blood cell count. Cerebrospinal fluid obtained on the first hospital day showed 22 WBC/high power field and an increased protein level of 82 mg/dl. Aetiological investigations, including anti-GM1, anti-GM2, anti-GD1a, anti-GM1b, anti-GT1a, anti-GQ1b, anti-GD1b, anti-GT1b, and anti-GQ1b, were all negative, and the level of anti-acetylcholine receptor antibody, serum cytomegalovirus, and herpetic simplex virus were all normal. Serum titres of influenza A and B, measles, mumps, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus, herpes simplex virus, rubella, and mycoplasma were also normal. Cranial magnetic resonance (MR) imaging and MR angiography showed no abnormal lesions. EEG findings were normal. Nerve conduction studies showed decreased F wave persistence in the arms. Motor and sensory nerve conduction velocities were well maintained.

On the basis of the neurological findings, we established a diagnosis of the Miller Fisher syndrome. The patient was treated with a 12 litre plasma exchange over six days, followed by high dose intravenous gamma globulin (400 mg/kg/day for five continuous days).

There was no chest pain during admission to our hospital; however, an ECG on the first hospital day showed sinus tachycardia with slightly elevated ST segments in leads V3–V5. T waves were inverted in leads I, II, AVL, and V3–6 on the fifth day. These findings, in turn, prompted further investigations and led to the diagnosis of Miller Fisher syndrome.
conjunct with the previous episode of chest tightness, led us to suspect acute coronary syndrome, and we undertook coronary angiography. Although the coronary arteries were free of any lesions, a left ventricular angiogram showed severe hypokinesia in the anterolateral, apical, and diaphragmatic segments, with an ejection fraction of 34%. Provocative vasospasm was not confirmed. Maximum creatine kinase MB release was 8.0 ng/ml (normal < 5.0 ng/ml). A left ventricular angiogram on the 13th hospital day showed an improvement in the hypokinesia, with an ejection fraction of 44%. There were no specific abnormal findings on myocardial biopsy. Serum noradrenaline (norepinephrine) concentrations were increased to 810 ng/l, 1160 ng/l, and 549 ng/l on the seventh, 14th, and 78th day, respectively (normal 90–420 ng/l). Thallium-201 scintigraphy on the ninth day showed only mild hypoperfusion in the lateral wall; however, 123I-metaiodobenzylguanidine (MIBG) scintigraphy done on the 12th day revealed a decrease in uptake in the anterior, inferior, and lateral walls [A]. The uptake had recovered by the 70th day [B].

**Comment**

In this case, serum anti-GQ1b antibody was negative despite its common association with Miller Fisher syndrome. However, we feel that the triad of ataxia, areflexia, and ophthalmoplegia in association with dissociation of proximal and distal motor units could not be ruled out. We suggested the involvement of cardiac autonomic nervous system. This cardiac syndrome mimicking acute myocardial infarction is supported by the detection of immune complexes in the serum or cerebrospinal fluid (CSF) of some patients.

**References**


**No evidence of type 1 or type 3 hypersensitivity mechanism in amoxicillin/clavulanic acid induced aspeptic meningitis**

Drug induced aspecic meningitis has been reported in response to various agents, in particular non-steroidal anti-inflammatory drugs, intravenous immunoglobulins, anti-CD3 monoclonal antibody (OKT3), and antibiotics. Hypersensitivity reactions (especially type 1 and type 3) have been invoked as the cause by many investigators. This hypothesis is supported by the detection of immune complexes in the serum or cerebrospinal fluid (CSF) of some patients.

To our knowledge, only two cases of aspecic meningitis induced by amoxicillin with or without clavulanic acid have been reported. We report a third case of probable amoxicillin induced aspecic meningitis where we performed laboratory studies for type 1 or type 3 hypersensitivity mechanisms.

**Case report**

A 62 year old man presented to our hospital because of fever (up to 40°C) and severe headache for four days. Both had begun approximately six hours after the intake of one tablet of 500 mg amoxicillin plus 125 mg clavulanic acid (Augmentan®, SmithKline Beecham) as antibiotic prophylaxis before a planned dental surgical procedure. He had discontinued the antibiotic after two tablets and cancelled the appointment with the dentist. Five weeks before, he had already had to cancel the planned operation, because he had exactly the same (but more severe) signs and symptoms, also approximately six hours after the intake of one tablet of amoxicillin/ clavulanic acid. Following discontinuation of the prophylactic antibiotic (after two tablets), the fever and headache had subsided over the course of three weeks without any treatment.
Tests were not performed during that episode. He could not remember having taken amoxicillin/clavulanic acid before that first occasion. He did not report any accompanying “allergic” signs, such as facial oedema, conjunctivitis, or rash during either of the two episodes, and he had no previous history of allergy or connective tissue disorder. His neurological status was unremarkable, and in particular there was no neck stiffness. His physical status was also normal except for a body temperature of 38.2°C. Cranial computed tomography revealed no abnormalities. CSF examination showed the following results: leukocyte count 54 cells/μl (82% lymphocytes, 12% monocytes, 4% lymphoid cells, 2% granulocytes); glucose 62 mg/dl (serum 98 mg/dl); protein 94 mg/dl; Q13.4 (1000 × CSF albumin/serum albumin, normal < 7.4); IgG index 9.38 (1000 × CSF IgG/serum IgG); oligoclonal bands negative. Bacterial and fungal cultures from CSF were negative. Blood analyses were also normal except for a slightly raised C reactive protein (1.1 mg/dl, normal < 0.5 mg/dl). Additional investigations did not support an underlying type 1 or type 3 hypersensitivity mechanism, as no specific IgE to amoxicillin (<0.35 IU/ml) or immune complexes interacting with C1q (<20 IE/ml) were detected in his serum or CSF. Without further treatment, he recovered completely within one week.

Comment
On the basis of the history and findings (two identical episodes of high fever and headache shortly after intake of the prophylactic antibiotic, and sterile CSF pleocytosis at least during the second episode), we diagnosed probable amoxicillin/clavulanic acid induced as ectic meningitis. However, we could not find any evidence suggesting an underlying type 1 or type 3 hypersensitivity reaction. Further studies are therefore warranted.

S Kastenbauer, H-W Pfister
Department of Neurology, Klinikum Großhadern, Ludwig-Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany

M Wick
Department of Clinical Chemistry, Klinikum Großhadern, Correspondence to: Dr Kastenbauer; stefan@kastenbauer.de

References

Another adverse effect of aspirin: bilateral vestibulopathy

Widely used for more than 2000 years, salicylic acid has numerous beneficial effects. It may also lead to several adverse reactions, affecting for instance the auditory system. Persistent dysfunction of the vestibular system, however, has not yet been described. We report a patient who took 5–6 g aspirin a day for three days for arthralgia. Subsequently he felt unsteady and had oscillopsia while walking, but no tinnitus or hypacusis. Caloric irri-

ation revealed a bilateral vestibulopathy which was most probably caused by the direct effect of aspirin on the vestibular hair cells.

Case report
A 61 year old teacher took 5–6 g aspirin a day for three days to treat his arthralgia, but no other drugs during this period. Two or three days later he felt unsteady while walking. This problem was worse on uneven ground and in the dark. During head movements and while walking he perceived apparent motion of the visual scene and his vision was blurred. Hear-

ing was normal and he did not complain of tinnitus. He had not had vertigo or hearing problems previously, and his family history was also unremarkable. Though he had had monoclonal (IgG lambda) gammopathy for five years, a bone marrow biopsy proved normal, and thus his condition had been diagnosed as “monoclonal gammopathy of unknown significance.”

As all his symptoms persisted, he came to our dizziness unit nine months later. The Halmagyi-Curthoys test (head impulse test to evaluate the function of the semicircular canals) was pathological and revealed a dynamic deficit of the horizontal semicircular canal bilaterally. Romberg testing showed increased sway which worsened when the eyes were closed. His gait was based and also worsened with the eyes closed. However, his hearing was normal, and he had no cerebellar signs.

Electronystagmography revealed a signifi-
cant bilateral caloric hyporesponsiveness (peak slow-phase velocity of the caloric nystagmus during irrigation with 44°C warm water: right ear, 2°/s; left ear, 5°/s; and 30°C cold water: right ear, 5°/s; left ear, 5°/s). Further, the pre- and postrotatory nystagmus lasted less than three seconds and showed a gain of <0.2. Hearing tests, including an audiogram, were normal. Blood tests for other possible causes of bilateral vestibulopathy (antibodies against inner ear structures, antimicrobial antibodies, anticentrosomal antibodies, rheumatic factor, vitamin B-12, folate acid, and so on), as well as high resolution magnetic resonance imaging of the cerebello-pontine angle and labyrinth were normal. As mentioned above, testing of the serum revealed the presence of monoclonal IgG- lambda gammopathy (total protein 8.7 g/dl (normal range 6.0 to 8.0 g/dl); IgG concentra-
tion 28.2 g/dl (normal range 7.0 to 16.0 g/dl)).

Comment
Pathophysiologically, the patient’s complaints are fully explained by bilateral vestibulopathy: the oscillopsia is caused by a defect of the vestibulo-ocular reflex, and the unsteadiness by a defect of the vestibulospinal reflexes, especially in darkness when vision cannot substitute for absent vestibular function. The time course of symptom development following the ingestion of a high dose of aspirin provides strong evidence that the isolated and persistent bilateral vestibulopathy was caused by the drug. Although aspirin induced bilateral vestibulopathy has not been reported before, it is likely that other patients taking aspirin have developed it, as bilateral vestibulopathy is often overlooked.

For more than 150 years it has been known that high doses of salicylates can cause tinnitus, loss of absolute acoustic sensitivity, and alterations of perceived sounds, which may develop in the initial days of treatment. It is also known that the susceptibility of individual subjects to salicylate induced inner ear toxicity varies greatly, but why this is so is unclear. Various attempts have been made to explain the toxic effects of salicylic acid. Otoacoustic emissions have been used to show that salicylates cause changes in the mechanosensory functioning of the cochlea; in particular, spontaneous emissions are decreased. Histopathological animal studies have revealed significant changes of only the outer hair cell lateral membrane. In vitro experiments have shown that the fast motile responses of outer hair cells are reduced. As regards the underlying mechanisms, aspirin seems to directly inhibit the mecha

nelectrical transduction process by partitioning the salicylate molecules in the membrane of hair cells. These latter findings suggest to us that this newly described adverse reaction to aspirin may be related to our patient’s monoclonal IgG-lambda gammopathy. The raised IgG concentra-
tion could have promoted such partitioning of the molecules in the hair cell membrane, assuming they are able to enter the endolymphatic space. However, this does not explain the isolated impairment of the vestibular function.

From a clinical point of view, it is relevant to consider this additional adverse effect of aspirin, especially as it is unpredictable owing to varying individual susceptibilities. If a patient has taken higher dosages of aspirin and com-

plains of dizziness, his vestibular function should be tested for bilateral vestibulopathy.

M Strupp, K Jahn, T Brandt
Department of Neurology, Klinikum Großhadern, Correspondence to: Michael Strupp; mstrupp@hefo.med.uni-muenchen.de

References

www.jnnp.com